Review anchor
Monoamine oxidase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Monoamine oxidase
CHEMBL2095205
PROTEIN FAMILY
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Monoamine oxidase as ChEMBL target CHEMBL2095205, mapped to UniProt P21397. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2095205
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21397
Amine oxidase [flavin-containing] A
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Monoamine oxidase matters
Monoamine oxidase is reviewed as Amine oxidase [flavin-containing] A (UniProt P21397); Monoamine oxidase shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 232 compounds, and 56 assays, with lead potency reaching pChEMBL 9.1.
Protein context
Amine oxidase [flavin-containing] A
Amine oxidase [flavin-containing] A Sequence length is 527 aa.
Review this target as Monoamine oxidase, mapped to UniProt P21397. ChEMBL maps the protein component as Amine oxidase [flavin-containing] A. Sequence length is 527 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P21397
Protein
Disease context
major depressive disorder
Monoamine oxidase shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include IPRONIAZID, ISOCARBOXAZID, NIALAMIDE.
Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include IPRONIAZID, ISOCARBOXAZID, NIALAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
3 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 232 compounds, and 56 assays for this target. The dominant activity type is IC50. CHEMBL14640 is the current potency anchor at pChEMBL 9.1.
Use CHEMBL14640 as the tractability anchor when discussing potency (pChEMBL 9.1).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Monoamine oxidase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21397, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why major depressive disorder is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
232
Total Compounds
56
Total Assays
1
Approved Drugs
IC50: 62.0, KI: 54.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL14640
|
9.1 | Ki | — |
|
|
No preferred name
CHEMBL275970
|
8.7 | Ki | — |
|
|
No preferred name
CHEMBL14210
|
8.6 | Ki | — |
|
|
No preferred name
CHEMBL93845
|
8.2 | Ki | — |
|
|
No preferred name
CHEMBL147569
|
8.2 | Ki | — |
Source Header